Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.

A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...

The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.

US-based pharmaceutical company MSD has published results from a Phase III trial of a potential combination therapy for ...

LifeSci Capital analyst Cory Jubinville, PhD has maintained their bullish stance on LRMR stock, giving a Buy rating today.Pick the best stocks ...

Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...

Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone has met the primary endpoint in the NEXUS trial ...

Spruce Biosciences (SPRB) “announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of ...

Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone met the primary endpoint in the NEXUS trial for ...